|
|
Changes in renal function and morphological variations of kidney diseases in rheumatoid arthritis patients |
Yan Tanga,Yuliya Varavkob,*( ),Raisa Aringazinac,Irina Menshikovad
|
aCollege of Medical Technology, Yongzhou Vocational Technical College, Yongzhou, China bDepartment of Internal Diseases Propaedeutics, Irkutsk State Medical University, Irkutsk, Russian Federation cDepartment of Internal Diseases No. 1, Non-Commercial Joint-Stock Society “West Kazakhstan Marat Ospanov Medical University”, Aktobe, Kazakhstan dDepartment of Hospital Therapy No. 1, I. M. Sechenov First Moscow State Medical University of Ministry of Health of Russian Federation (Sechenov University), Moscow, Russian Federation |
|
|
Abstract Objective: Rheumatoid nephropathy is one of the most severe extra-articular manifestations of rheumatoid arthritis (RA) associated with a very unfavorable prognosis. This study aimed to identify changes in renal function and morphological variations of kidney diseases in RA patients. Methods: The study enrolled patients (126 patients) between 18 and 55 years of age with a confirmed active RA of more than 12 months. Each patient underwent the following range of laboratory and instrumental research methods: general clinical analysis of blood and urine, performing urinalysis according to Nechiporenko method; determining daily proteinuria; determining the blood content of glucose, urea, creatinine, uric acid, total bilirubin, liver transaminase level, ionogram, lipidogram, and coagulogram; determining the blood content of rheumatoid factor, anti-streptolysin O, and C-reactive protein; and X-ray of the joints of hands and feet. Renal function was examined by estimating glomerular filtration rate, tubular reabsorption index, and renal functional reserve. For studying the morphological changes in the kidneys under ultrasound examination, renal biopsy was performed in 31 patients with RA with urinary syndrome (proteinuria more than 0.3 g per day and hematuria). Results: Nephropathy in RA is characterized by impaired renal function and manifested by an increased blood creatinine and a decrease in glomerular filtration rate and renal functional reserve. Among morphological variations of nephropathy at RA, mesangial proliferative glomerulonephritis prevails, accounting for 48.4% of patients. Other disorders include the secondary amyloidosis (29.0% of patients), tubulointerstitial nephritis (16.1%), membranous glomerulonephritis (3.2%), and focal-segmental glomerulosclerosis (3.2%). Conclusion: Kidney damage is a common systemic manifestation of RA with a long and active course, a major nephropathy trigger.
|
Received: 01 March 2022
Available online: 20 April 2024
|
Corresponding Authors:
* E-mail address: roza1983@mail.ru (Y. Varavko).
|
|
|
Indicator | AHPs (n=30) | Patients with RA and nephropathy | RA patients without kidney damage (n=36) | With MAU (n=46) | With PU (n=44) | Creatinine, μmol/L | 66.28±3.15 | 79.83±3.46b | 95.29±4.03b,c,d | 69.13±2.81 | Urea, mmol/L | 4.39±0.42 | 5.67±0.51 | 4.65±0.46 | 4.41±0.40 | Leukocytes in 1 mL urinee | 460.30±40.6 | 509.70±52.80 | 1137.40±73.20b,c,d | 482.50±47.30 | Erythrocytes in 1 mL of urinee | 246.50±29.7 | 261.30±40.60 | 995.40±51.69b,c,d | 275.10±32.80 | RFR, mL/min | 108.47±2.51 | 99.62±2.74 | 87.19±3.11b,c,d | 106.15±1.99 | Daily PU, g/day | 0.02±0.001 | 0.15±0.003b,c | 0.52±0.01b,c,d | 0.03±0.001 | MAU, g/L | 0.008±0.001 | 0.024±0.002b,c | NAf | 0.01±0.001 | TR, % | 99.07±0.1 | 99.02±0.16 | 98.97±0.14 | 99.06±0.13 | RFR, % | 19.10±0.53 | 13.31±0.45b,c | 5.38±1.37b,c,d | 18.27±0.62 |
|
Indicators of renal function in patients with active RAa.
|
|
Morphological variations of kidney damage in rheumatoid arthritis patients (n=31). TIN, tubulointerstitial nephritis; SA, secondary amyloidosis; MGN, membranous glomerulonephritis; MPGN, mesangial proliferative glomerulonephritis; FSGS, focal segmental glomerulosclerosis.
|
[1] |
Minichiello E, Semerano L, Boissier MC. Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2016; 83:625e30.
doi: S1297-319X(16)30129-4
pmid: 27616690
|
[2] |
Otón T, Carmona L. The epidemiology of established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2019; 33: 101477. https://doi.org/10.1016/j.berh.2019.101477.
doi: 10.1016/j.berh.2019.101477
|
[3] |
Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int 2021; 41:863e77.
doi: 10.1007/s00296-020-04731-0
pmid: 33175207
|
[4] |
Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of rheumatoid arthritis 1990e2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis 78:1463e71.
doi: 10.1136/annrheumdis-2019-215920
|
[5] |
Abhishek A, Doherty M, Kuo CF, Mallen CD, Zhang W, Grainge MJ. Rheumatoid arthritis is getting less frequentdresults of a nationwide population-based cohort study. Rheumatology 2017; 56:736e44.
doi: 10.1093/rheumatology/kew468
pmid: 28064207
|
[6] |
Favalli EG, Biggioggero M, Crotti C, Becciolini A, Raimondo MG, Meroni PL. Sex and management of rheumatoid arthritis. Clin Rev Allergy Immunol 2019; 56:333e45.
doi: 10.1007/s12016-018-8672-5
|
[7] |
Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004e2014. Rheumatol Int 2017; 37:1551e7.
doi: 10.1007/s00296-017-3726-1
|
[8] |
Van den Hoek J, Boshuizen HC, Roorda LD, Tijhuis GJ, Nurmohamed MT, van den Bos GAM, et al. Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol Int 2017; 37:487e93.
doi: 10.1007/s00296-016-3638-5
pmid: 28032180
|
[9] |
Lacaille D, Avina-Zubieta JA, Sayre EC, Abrahamovicz M. Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap. Ann Rheum Dis 2017; 76:1057e63.
doi: 10.1136/annrheumdis-2016-209562
pmid: 28031164
|
[10] |
Lo J, Chan L, Flynn S. A systematic review of the incidence, prevalence, costs, and activity and work limitations of amputation, osteoarthritis, rheumatoid arthritis, back pain, multiple sclerosis, spinal cord injury, stroke, and traumatic brain injury in the United States: a 2019 update. Arch Phys Med Rehabil 2021;102:115e31.
|
[11] |
Karami J, Aslani S, Jamshidi A, Garshasbi M, Mahmoudi M. Genetic implications in the pathogenesis of rheumatoid arthritis; an updated review. Gene 2019; 702:8e16.
doi: S0378-1119(19)30290-2
pmid: 30904715
|
[12] |
Scherer HU, H?upl T, Burmester GR. The etiology of rheumatoid arthritis. J Autoimmun 2020; 110:102400.
doi: 10.1016/j.jaut.2019.102400
|
[13] |
Alam J, Jantan I, Bukhari SNA. Rheumatoid arthritis: recent advances on its etiology, role of cytokines and pharmacotherapy. Biomed Pharmacother 2017; 92:615e33.
doi: S0753-3322(17)31131-9
pmid: 28582758
|
[14] |
Deane KD, Holers VM. Rheumatoid arthritis pathogenesis, prediction, and prevention: an emerging paradigm shift. Arthritis Rheumatol 2021; 73:181e93.
doi: 10.1002/art.v73.2
|
[15] |
Derksen VFAM, Huizinga TWJ, Van Der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol 2017; 39:437e46.
doi: 10.1007/s00281-017-0627-z
pmid: 28451788
|
[16] |
Mellado M, Martínez-Mu?oz L, Cascio G, Lucas P, Pablos JL, Rodriguez-Frade JM. T cell migration in rheumatoid arthritis. Front Immunol 2015;6:384. https://doi.org/10.3389/fimmu.2015.00384.
|
[17] |
Petrukhina DA, Pletneva IV, Sysuev BB. Modern medicines (assortment) and trends in the improvement of dosage forms of hepatoprotective agents (review). Drug Dev Registr 2021; 10:38e46.
doi: 10.33380/2305-2066-2021-10-3-38-46
|
[18] |
Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Alvaro-Gracia JM, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis 2017; 76:948e59.
doi: 10.1136/annrheumdis-2016-210602
|
[19] |
Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949; 140:659e62.
doi: 10.1001/jama.1949.02900430001001
|
[20] |
Mori S, Yoshitama T, Hirakata N, Ueki Y. Prevalence of and factors associated with renal dysfunction in rheumatoid arthritis patients: a cross-sectional study in community hospitals. Clin Rheumatol 2017; 36:2673e82.
doi: 10.1007/s10067-017-3804-5
pmid: 28884373
|
[21] |
Raksasuk S, Ungprasert P. Patients with rheumatoid arthritis have an increased risk of incident chronic kidney disease: a systematic review and meta-analysis of cohort studies. Int Urol Nephrol 2020; 52:147e54.
doi: 10.1007/s11255-019-02346-4
pmid: 31820358
|
[22] |
Tokoroyama T, Ando M, Setoguchi K, Tsichiya K, Nitta K. Prevalence, incidence, and prognosis of chronic kidney disease classified according to current guidelines: a large retrospective cohort study of rheumatoid arthritis patients. Nephrol Dial Transplant 2017; 32:2035e42.
|
[23] |
Chebotareva NV, Guliaev SV, Androsova TV, Milovanova LY. Chronic kidney disease in rheumatoid arthritis patients: prevalence, risks factors, histopathological variants. Ter Arkh 2019; 91:129e33.
doi: 10.26442/00403660.2019.05.000255
pmid: 32598687
|
[24] |
Rekalov D, Prytkova A, Kulynych R, Protsenko G, Protsenko V. Nephropathy in early rheumatoid arthritis patients: does a significant risk exist? Georgian Med News 2018; 274:79e88.
|
[25] |
Bortnikova VV, Karabaeva VV, Krepkova LV, Mizina PG, Babenko AN, Mikheeva NS, et al. A retrospective analysis of the clinical studies of a drug “Flakozid” in the treatment of diseases of the hepatobiliary system. Drug Dev Registr 2021; 10:100e4.
doi: 10.33380/2305-2066-2021-10-3-100-104
|
[26] |
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69:1580e8.
doi: 10.1136/ard.2010.138461
|
[27] |
Nechiporenko AZ, Ivanova SB. Significance of cytological study of the urine in the diagnosis of cancer of the urinary bladder. Urol Nefrol 1968; 33:30e4.
|
[28] |
Bosch JP, Saccaggi A, Lauer A, Ronco C, Belledonne M, Glabman S. Renal functional reserve in humans. Effect of protein intake on glomerular filtration rate. Am J Med 1983; 75:943e50.
|
[29] |
Kark RM, Muehrcke RC. Biopsy of kidney in prone position. Lancet 1954; 266:1047e9.
doi: 10.1016/s0140-6736(54)91618-9
pmid: 13164322
|
[30] |
Vinicki JP, Pellet SC, De Rosa G, Dubinsky D, Laborde HA, Marini A, et al. Analysis of 65 renal biopsies from patients with rheumatoid arthritis (1976e2015): change in treatment strategies decreased frequency and modified histopathological findings. J Clin Rheumatol 2015; 21:335e40.
doi: 10.1097/RHU.0000000000000302
|
[31] |
M?ller B, Pruijm M, Adler S, Scherer A, Viliger PM, Finckh A. Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Ann Rheum Dis 2015; 74:718e23.
doi: 10.1136/annrheumdis-2013-204078
pmid: 24356672
|
[32] |
Meshkovskiy AP, Beregovykh VV, Shestakov VN, Pyatigorskaya NV, Aladysheva ZhI, Nikolenko NS, et al. Procedure for reviewing pharmaceutical inspections in the Eurasian Economic Union (review). Drug Dev Registr 2021; 10: 138e46.
|
[33] |
Marcucci E, Bartoloni E, Alunno A, Leone MC, Cafaro G, Luccioli F, et al. Extra-articular rheumatoid arthritis. Reumatismo 2018; 70:212e24.
doi: 10.4081/reumatismo.2018.1106
pmid: 30570239
|
[34] |
Hickson LJ, Crowson CS, Gabriel SE, McCarthy JT, Matteson EL. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis 2014; 63:206e13.
doi: 10.1053/j.ajkd.2013.08.010
pmid: 24100126
|
No related articles found! |
|
|
|
|